Number One With A Bullet: Eylea Takes Top Spot In Medicare Part B Drugs
Executive Summary
Regeneron’s Eylea is the new holder of the number one spot in Medicare Part B prescription drug payments. It is also the fastest growing entrant on the top-ten list tracked by MedPAC. That is a sign of great commercial success – but could be an uncomfortable spotlight.
You may also be interested in...
Could Medicare 340B Payment Cuts Lead Hospitals To Buy At List Price?
Pew Charitable Trusts' Allan Coukell warns the Centers for Medicare and Medicaid Services that its proposal to reduce Medicare Part B drug payments to 340B hospitals may have 'unintended consequences.'
Rituxan Could Be Top Source Of Price Inflation Rebates In Medicare Part B
HHS Office of Inspector General estimates $1.4bn to $1.8bn could have been saved in Medicare Part B in 2015 if manufacturers provided rebates when drug prices increased faster than inflation.
Exclusive Remicade Contracts Are Slowing Biosimilar Uptake
Exclusive contracts for J&J's Remicade have posed challenges for Pfizer's Inflectra in the commercial insurance market, the biosimilar's maker said during its second quarter earnings call.